Topic Hub
8 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 8 of 8 clinical reviews.
A detailed critique of the STEP-1 Extension trial examining enrollment biases, follow-up gaps, generalizability concerns, statistical caveats, and conflict-of-interest disclosures around semaglutide discontinuation and weight regain.
Read clinical reviewA detailed methodological analysis of the STEP-1 Extension trial examining weight regain after semaglutide discontinuation, covering randomization, estimand framework, statistical approach, and interpretive implications.
Read clinical reviewA deep-dive into the cost-effectiveness analyses, payer-coverage implications, and individual patient value calculations that emerged from the STEP-1 Extension trial on semaglutide discontinuation and weight regain.
Read clinical reviewDeep-dive into the STEP-1 Extension trial results showing weight regain after semaglutide 2.4 mg discontinuation, with effect sizes, secondary endpoints, and time-course analysis.
Read clinical reviewDeep-dive into STEP-1 Extension pre-specified and post-hoc subgroup analyses by age, sex, BMI, baseline biomarkers, and race/ethnicity, examining differential weight regain after semaglutide discontinuation.
Read clinical reviewA deep-dive into the STEP-1 Extension trial showing two-thirds of semaglutide weight loss was regained within one year of stopping treatment, confirming obesity requires ongoing pharmacotherapy.
Read clinical reviewA deep-dive into STEP-1 Extension follow-up data: weight regain trajectories, cardiometabolic reversal, methodology critique, and what 1-year post-discontinuation data tells us about the chronic-disease model of obesity treatment.
Read clinical reviewA deep-dive into the clinical implications of the STEP-1 Extension trial: which prescribing patterns shifted, which guidelines updated, and what the weight-regain data means for patients who differ from the trial population.
Read clinical review